← back to search

Gene V. Wallenstein

Newcastle University · GB
🔎 Find collaborators in Rheumatology · Hematology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Rheumatology · Hematology
Research interest
Research interests include Medicine, Tofacitinib, Rheumatoid arthritis, Janus kinase inhibitor, Placebo, and Adalimumab.
h-index
citations
2,662
works
8
NIH funding
primary concept
email

Recent publications

Renal Flares and Health-Related Quality of Life Among Patients with Lupus Nephritis: A Post Hoc Analysis of Control Arm Data from the LUNAR Phase 3 Clinical Trial
Rheumatology and Therapy 2026cited by 0position: middledoi
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
Lara D. Veeken 2016cited by 78position: lastdoi
Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
Arthritis Care & Research 2016cited by 77position: lastdoi
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
Arthritis Research & Therapy 2015cited by 72position: middledoi
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
New England Journal of Medicine 2014cited by 771position: middledoi
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
The Lancet 2013cited by 717position: middledoi
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
New England Journal of Medicine 2012cited by 936position: middledoi
THU0151 Effects of tofacitinib (CP-690,550), an oral janus kinase inhibitor, or adalimumab on patient reported outcomes in a phase 3 study of active rheumatoid arthritis
Annals of the Rheumatic Diseases 2012cited by 11position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David Gruben · Newcastle University7 papers (2012–2016)Samuel H. Zwillich · Newcastle University7 papers (2012–2016)Roy Fleischmann · Metroplex Clinical Research Center5 papers (2012–2016)Tamás Koncz · Pfizer (United States)5 papers (2012–2016)John Bradley · Partners for Health and Development in Africa4 papers (2012–2014)Sriram Krishnaswami · Newcastle University4 papers (2012–2016)Ronald van Vollenhoven · Amsterdam Neuroscience4 papers (2012–2016)Vibeke Strand · Stanford University4 papers (2012–2016)Bethanie Wilkinson · Novavax (United States)4 papers (2012–2016) · 3 papers (2012–2016)Joel M. Kremer · Research Foundation for the State University of New York2 papers (2015–2016)Stanley Cohen · Southwestern Medical Center1 papers (2012–2012)Chuanbo Zang · Weifang Medical University1 papers (2014–2014) · 1 papers (2013–2013) · 1 papers (2012–2012)Gerd R Burmester · Humboldt-Universität zu Berlin1 papers (2013–2013) · 1 papers (2013–2013)Cristiano A. F. Zerbini · Centro Paulista de Investigação Clinica1 papers (2013–2013) · 1 papers (2012–2012) · 1 papers (2013–2013)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Rheumatology · Hematology →